Breast Cancer

, Volume 19, Issue 1, pp 16–22

Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study

  • Kais Aldabbagh
  • Stéphane Pouderoux
  • Lise Roca
  • Sylvain Poujol
  • Michel Fabbro
  • Gilles Romieu
  • William Jacot
Original Article

DOI: 10.1007/s12282-010-0240-7

Cite this article as:
Aldabbagh, K., Pouderoux, S., Roca, L. et al. Breast Cancer (2012) 19: 16. doi:10.1007/s12282-010-0240-7

Abstract

Background

Since 2004, metastatic breast cancer patients pretreated with anthracyclines, taxanes, and capecitabine have been treated in our institution with a combination of mitomycin C, methotrexate, and VP-16 (VMM). We report in this study a retrospective analysis of the activity and safety of the VMM combination.

Methods

Patients were treated with a combination of VP-16 (100 mg/m2 on day 1), mitomycin C (MMC, 10 mg/m2 on day 1), and methotrexate (MTX, 12.5 mg/m2 twice a day on day 2 and 3) in a 21-day cycle.

Results

Seventy-five patients were treated. Median age was 48 years. A total of 256 cycles were administered. Median relative dose intensities were 0.87, 0.87, and 0.95 for VP-16, MMC, and MTX, respectively. Objective response rate was 31%, with a clinical benefit rate of 47%. Median response duration was 5.8 months. Median disease stabilization duration was 9.1 months. Median progression-free survival (PFS) was 4.2 months with a 14% 1-year PFS rate. Median overall survival (OS) was 6.2 months, with a 25% 1-year OS rate. Myelosuppression was the most common toxicity. The most commonly reported extra-hematological adverse event (AE) was fatigue. Emesis and alopecia were rarely reported.

Conclusions

This combination appears to be effective and well tolerated in this heavily pretreated metastatic breast cancer population.

Keywords

Breast cancerMethotrexateMitomycin CEtoposideToxicityEfficacy

Copyright information

© The Japanese Breast Cancer Society 2010

Authors and Affiliations

  • Kais Aldabbagh
    • 1
  • Stéphane Pouderoux
    • 1
  • Lise Roca
    • 2
  • Sylvain Poujol
    • 3
  • Michel Fabbro
    • 1
  • Gilles Romieu
    • 1
  • William Jacot
    • 1
  1. 1.Department of Medical OncologyCRLC Val d’AurelleMontpellier Cedex 5France
  2. 2.Department of BiostatisticsCRLC Val d’AurelleMontpellierFrance
  3. 3.Oncopharmacology DepartmentCRLC Val d’AurelleMontpellierFrance